Education
About Us
Working with TipRanks
Follow Us
Orexo AB (SE:ORX)
:ORX
ORX Stock Chart & Stats
kr25.00
kr0.22(1.39%)
At close: 4:00 PM EST
kr25.00
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr12.50 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr797.36M
Enterprise Valuekr1.53B
Total Cash (Recent Filing)kr121.30M
Total Debt (Recent Filing)kr495.60M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Feb 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding34,710,640
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-4.78
Price to Sales (P/S)1.02
P/FCF Ratio-16.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr12.50 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr797.36M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Feb 05, 2026 which is in 48 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Oct 23, 2025. The company reported -kr0.9 earnings per share for the quarter, missing the consensus estimate of -kr0.5 by -kr0.4.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.3.
How many shares outstanding does Orexo AB have?
Orexo AB has 34,710,640 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr0.9 in its last earnings report, missing expectations of -kr0.5. Following the earnings report the stock price went down -20.133%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (ORX) is a Swedish pharmaceutical company focused on developing and commercializing innovative pharmaceuticals for the treatment of opioid dependence and pain management. The company operates primarily in the pharmaceutical sector, with a core portfolio that includes its flagship product, Zubsolv, which is used for the treatment of opioid use disorder. Orexo is also involved in research and development of new therapies, aiming to address unmet medical needs within the pain management and addiction treatment markets.
ORX Company Deck
ORX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant R&D progress and strategic developments, such as the BARDA partnership for OX390 and positive growth in the U.S. commercial segment. However, financial challenges remain, including negative EBITDA, revenue declines in the U.S. commercial business, and market uncertainties for OX640. Despite these challenges, strategic initiatives and partnerships indicate potential for future growth.View all SE:ORX earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―